Acarix is a Swedish MedTech company marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.

We are committed to bringing about a change in the early warning and assessment of cardiac and vascular diseases. Our latest news can be found below.

2019 10 28

Acarix represented at Redeye Investor After Work, Scandic Rubinen, Gothenburg

Per Perssons presentation available under news

2019 10 14

Acarix deltar på Aktiedagen den 15 oktober på operaterrassen, Karl XII:s torg, Stockholm

VD Per Persson, presenterar klockan 16.00. Aktiedagen anordnas av Aktiespararna.

2019 10 07

Acarix at DGK Herztage Berlin 10-12 Okt 2019

Meet the expert Dr Klaus Remde at Stand 19 im Foyer, Saal Maritim

2019 09 19

Investor Forum 17 september 2019

Per Persson CEO, Acarix invited to Redeye investor forum.

2019 09 06

CADScor®System ESC Paris 2019

The new guideline recommends looking at the clinical likelihood of obstructive CAD for each individual to choose the appropriate diagnostic procedure.

2019 08 28

Jörg Domes joins Acarix

I am very happy to announce that Jörg Domes will join Acarix in the role of Sales Director on October 1st, 2019. Jörg will take the overall responsibility for Germany, Austria and Switzerland, the DACH region.